痛风患者的骨质疏松性骨折、诊断活动与治疗现状
基于美国风湿病学会RISE注册与Medicare数据(2015-2021)的回顾性队列研究显示,痛风患者基线骨保护治疗使用率仅5%,低于骨关节炎(OA)的11.8%;痛风患者非椎体骨质疏松性骨折发生率较OA(IRR 1.4)和软组织风湿病(STR,IRR 2.0)更高,但随访期间骨保护治疗使用仍不充分。
要点
- 痛风患者基线骨保护治疗使用率5%,低于OA的11.8%和STR的9.0%。
- 痛风患者随访期间骨保护治疗使用率仅2.0%-3.4%,显著低于对照人群。
核心结论
- 痛风患者骨质疏松性骨折发生率高于OA和STR患者,且骨折危险因素(如慢性肾病、糖皮质激素使用)更多,但接受骨保护治疗的比例更低。
研究设计与样本
- 回顾性队列研究,使用美国风湿病学会RISE注册与Medicare索赔数据(2015-2021),按年龄±2岁、性别、种族和入组季度1:1精确匹配OA和STR对照患者。
主要发现
- 痛风患者基线骨保护治疗使用率为5%,OA为11.8%,STR为9.0%。
- 痛风患者基线骨质疏松性骨折和骨质疏松诊断患病率分别为1.4%和7.1%,OA为2.6%和15.4%,STR为3.4%和30.7%。
- 痛风患者非椎体骨质疏松性骨折发生率较OA高(IRR 1.4,95%CI 1.1-1.8),较STR高(IRR 2.0,95%CI 1.3-3.1)。
- 随访期间骨保护治疗使用率:痛风2.0% vs OA 4.5%;痛风3.4% vs STR 10.3%。
临床怎么用
- 风湿免疫科医生应关注痛风患者骨质疏松风险评估,尤其对合并慢性肾病或使用糖皮质激素者。
- 痛风患者骨保护治疗使用率低,提示需加强骨质疏松筛查和干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with gout may be at high risk for developing osteoporosis and osteoporotic fractures, but osteoporosis may be under-recognized and inadequately managed for patients with gout. We aimed to describe osteoporotic fractures and diagnosis, dual x-ray absorptiometry utilization, and bone protective therapy patterns in patients with gout and comparator groups. METHODS: We conducted a retrospective cohort study using the American College of Rheumatology's Rheumatology Informatics System for Effectiveness registry linked to Medicare claims (2015-2021), with 1:1 exact matching (age ±2 years, sex, race, and enrollment quarter) to comparator patients with osteoarthritis (OA) and soft tissue rheumatism (STR). The sample size was determined by including all patients eligible for the study after removing those with exclusionary criteria (eg, inconsistent age or sex and immunomodulation during the baseline period). We examined medications, laboratory test results, bone protective therapies, and computed crude and adjusted incidence rates (IRs) and IR ratios (IRRs) for osteoporotic fractures. RESULTS: Only 5% of patients with gout used bone protective therapy at baseline, compared to 11.8% of patients with OA. Baseline osteoporotic fracture and osteoporosis diagnosis prevalence was 1.4% and 7.1% in patients with gout versus 2.6% and 15.4% in patients with OA. Approximately 9.0% of patients with gout and 23.2% of patients with STR used bone protective therapy at baseline. Baseline osteoporotic fracture and osteoporosis diagnosis prevalence was 1.9% versus 10.9% in patients with OA and 3.4% versus 30.7% in patients with STR. Higher nonvertebral osteoporotic fracture rates were observed in patients with gout compared to those with OA (IRR 1.4 [95% confidence interval (CI) 1.1-1.8]) and STR (IRR 2.0 [95% CI 1.3-3.1]). Bone protective therapies were infrequently used during follow-up (patients with gout 2.0% vs OA 4.5%; patients with gout 3.4% vs STR 10.3%). CONCLUSION: Patients with gout experienced greater rates of osteoporotic fracture and greater osteoporotic fracture risk factors (eg, chronic kidney disease and greater glucocorticoid use) compared to patients with OA and STR yet were less likely to receive bone protective therapies.
引用
- Holladay EE, Zhang J, Xie F, et al. Osteoporotic Fracture, Diagnostic Activity, and Treatment in Patients With Gout. Arthritis Care Res (Hoboken). 2026. PMID: 42573228. doi:10.1002/acr.80134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。